These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

247 related items for PubMed ID: 21700755

  • 1. Effect of partial inhibition of fatty acid oxidation by trimetazidine on whole body energy metabolism in patients with chronic heart failure.
    Fragasso G, Salerno A, Lattuada G, Cuko A, Calori G, Scollo A, Ragogna F, Arioli F, Bassanelli G, Spoladore R, Luzi L, Margonato A, Perseghin G.
    Heart; 2011 Sep; 97(18):1495-500. PubMed ID: 21700755
    [Abstract] [Full Text] [Related]

  • 2. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure.
    Fragasso G, Palloshi A, Puccetti P, Silipigni C, Rossodivita A, Pala M, Calori G, Alfieri O, Margonato A.
    J Am Coll Cardiol; 2006 Sep 05; 48(5):992-8. PubMed ID: 16949492
    [Abstract] [Full Text] [Related]

  • 3. Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure.
    Fragasso G, Perseghin G, De Cobelli F, Esposito A, Palloshi A, Lattuada G, Scifo P, Calori G, Del Maschio A, Margonato A.
    Eur Heart J; 2006 Apr 05; 27(8):942-8. PubMed ID: 16510466
    [Abstract] [Full Text] [Related]

  • 4. [Potentialities of cytoprotection in the treatment of chronic heart failure in patients with coronary heart disease].
    Fedorova TA, Il'ina IuV, Sotnikova TI, Rybakova MK.
    Klin Med (Mosk); 2004 Apr 05; 82(11):15-20. PubMed ID: 15656392
    [Abstract] [Full Text] [Related]

  • 5. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease.
    Vitale C, Wajngaten M, Sposato B, Gebara O, Rossini P, Fini M, Volterrani M, Rosano GM.
    Eur Heart J; 2004 Oct 05; 25(20):1814-21. PubMed ID: 15474696
    [Abstract] [Full Text] [Related]

  • 6. Trimetazidine and reduction in mortality and hospitalization in patients with ischemic dilated cardiomyopathy: a post hoc analysis of the Villa Pini d'Abruzzo Trimetazidine Trial.
    Di Napoli P, Di Giovanni P, Gaeta MA, Taccardi AA, Barsotti A.
    J Cardiovasc Pharmacol; 2007 Nov 05; 50(5):585-9. PubMed ID: 18030070
    [Abstract] [Full Text] [Related]

  • 7. Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy.
    Fragasso G, Piatti Md PM, Monti L, Palloshi A, Setola E, Puccetti P, Calori G, Lopaschuk GD, Margonato A.
    Am Heart J; 2003 Nov 05; 146(5):E18. PubMed ID: 14597947
    [Abstract] [Full Text] [Related]

  • 8. Effects of trimetazidine, a partial inhibitor of fatty acid oxidation, on ventricular function and survival after myocardial infarction and reperfusion in the rat.
    Mouquet F, Rousseau D, Domergue-Dupont V, Grynberg A, Liao R.
    Fundam Clin Pharmacol; 2010 Aug 05; 24(4):469-76. PubMed ID: 20030737
    [Abstract] [Full Text] [Related]

  • 9. [Clinical and hemodynamic efficacy of selective beta-blocker bisoprolol and cytoprotector trimetazidine in the treatment of chronic cardiac failure in patients with ischemic heart disease].
    Fedorova TA, Il'ina IuV, Sotnikova TI, Rybakova MK, Loshchits NV.
    Ter Arkh; 2004 Aug 05; 76(3):62-8. PubMed ID: 15108463
    [Abstract] [Full Text] [Related]

  • 10. [Effects of trimetazidine on serum oxygen free radicals in congestive heart failure].
    Ma QL, Xie Y, Zhang SD.
    Hunan Yi Ke Da Xue Xue Bao; 2002 Dec 28; 27(6):527-9. PubMed ID: 12658930
    [Abstract] [Full Text] [Related]

  • 11. Trimetazidine shortens QTc interval in patients with ischemic heart failure.
    Zemljic G, Bunc M, Vrtovec B.
    J Cardiovasc Pharmacol Ther; 2010 Mar 28; 15(1):31-6. PubMed ID: 19966175
    [Abstract] [Full Text] [Related]

  • 12. Accurate determination of energy needs in hospitalized patients.
    Boullata J, Williams J, Cottrell F, Hudson L, Compher C.
    J Am Diet Assoc; 2007 Mar 28; 107(3):393-401. PubMed ID: 17324656
    [Abstract] [Full Text] [Related]

  • 13. Effect of trimetazidine on quality of life in elderly patients with ischemic dilated cardiomyopathy.
    Marazzi G, Gebara O, Vitale C, Caminiti G, Wajngarten M, Volterrani M, Ramires JA, Rosano G, Fini M.
    Adv Ther; 2009 Apr 28; 26(4):455-61. PubMed ID: 19396409
    [Abstract] [Full Text] [Related]

  • 14. Trimetazidine potentiates the effects of exercise training in patients with ischemic cardiomyopathy referred for cardiac rehabilitation.
    Belardinelli R, Lacalaprice F, Faccenda E, Volpe L.
    Eur J Cardiovasc Prev Rehabil; 2008 Oct 28; 15(5):533-40. PubMed ID: 18797405
    [Abstract] [Full Text] [Related]

  • 15. Effect of partial fatty acid oxidation inhibition with trimetazidine on mortality and morbidity in heart failure: results from an international multicentre retrospective cohort study.
    Fragasso G, Rosano G, Baek SH, Sisakian H, Di Napoli P, Alberti L, Calori G, Kang SM, Sahakyan L, Sanosyan A, Vitale C, Marazzi G, Margonato A, Belardinelli R.
    Int J Cardiol; 2013 Mar 10; 163(3):320-325. PubMed ID: 23073279
    [Abstract] [Full Text] [Related]

  • 16. Relationship between acute improvement in left ventricular function to 6-month outcomes after cardiac resynchronization therapy in patients with chronic heart failure.
    Pires LA, Ghio S, Chung ES, Tavazzi L, Abraham WT, Gerritse B.
    Congest Heart Fail; 2011 Mar 10; 17(2):65-70. PubMed ID: 21449994
    [Abstract] [Full Text] [Related]

  • 17. Effects of trimetazidine on myocardial perfusion and left ventricular systolic function in type 2 diabetic patients with ischemic cardiomyopathy.
    Belardinelli R, Cianci G, Gigli M, Mazzanti M, Lacalaprice F.
    J Cardiovasc Pharmacol; 2008 Jun 10; 51(6):611-5. PubMed ID: 18574390
    [Abstract] [Full Text] [Related]

  • 18. [Metabolic therapy for heart failure].
    Loiacono F, Alberti L, Lauretta L, Puccetti P, Silipigni C, Margonato A, Fragasso G.
    Recenti Prog Med; 2014 Jun 10; 105(7-8):288-94. PubMed ID: 25072544
    [Abstract] [Full Text] [Related]

  • 19. Role of trimetazidine in management of ischemic cardiomyopathy.
    Bertomeu-Gonzalez V, Bouzas-Mosquera A, Kaski JC.
    Am J Cardiol; 2006 Sep 04; 98(5A):19J-24J. PubMed ID: 16931202
    [Abstract] [Full Text] [Related]

  • 20. [Plasma hemostasis and biochemical indices in trimetazidine treatment of patients with chronic heart failure].
    Tereshchenko SN, Drozdov VN, Levchuk NN, Demidova IV.
    Ter Arkh; 1998 Sep 04; 70(6):41-4. PubMed ID: 9695225
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.